No abstract

No abstract

Validation of the Ocular Surface Disease IndexQuestionnaire for Chilean patients Background: Ocular Surface Disease Index (OSDI) is the most commonly used questionnaire worldwide to detect dry eye disease. Although it is massively used in clinical practice in Chile, its use has not been validated yet in the country. Aim: To develop a cultural adaptation and to validate the OSDI questionnaire for the Chilean population. Material and Methods: For cultural adaptation, a translation, retro-translation and an expert panel review was carried out. The resulting questionnaire was applied to a pilot group of twelve participants and their comments were considered for the final questionnaire version. The final questionnaire was applied to a non-random sample of 200 patients aged 53 ± 17 years (75% women). Internal consistency and construct validity were evaluated by Cronbach's alpha and exploratory factor analysis respectively. Results: According to the OSDI score, 81% of respondents had dry eye (55% severe). Reliability was 0.91 and factor analysis resulted in three factors explaining 75.4% of the total variance. Conclusions: The OSDI questionnaire version obtained in this study demonstrated excellent internal consistency values and adequate construct validity making it applicable to clinical practice and dry eye research.

Background: Meibomian gland disfunction is a common finding in glaucoma patients under topical treatment. Objective:To evaluate and analyze the Meibomian morphology in patients with different Glaucoma Topical Treatments. Methods: Cross-sectional retrospective study. 88 patients: 15 control and 73 glaucoma patients classified: a) Latanoprost-Timololcarbonic anhydrase inhibitor b) Latanoprost-Timolol, c) Timolol, d) Latanoprost, and e) Travoprost-Timolol (Polyquad). Slit-lamp examination and OSDI® questionnaire was evaluated. Glandular number, length, thickness, tortuosity percentage and tarsal/ glandular area (Meiboscore) was obtained from each Meibography. Results: Control presented the highest gland number (21.2 ± 5.3 upper and 17,3 ± 5,68 lower eyelid), longest glands (6,0 ± 0,94 mm upper and 3,2 ± 0,85 mm lower eyelid), thinnest glands (0,6 ± 0,14 mm upper and 0,8 ± 0,15 lower eyelid) and lower upper eyelid Meiboscore (63,3 ± 12,68%). Latanoprost-Timolol and carbonic anhydrase inhibitor presented the lowest tortuosity (27,1 ± 18,34% upper and 12,9 ± 13,99% lower eyelid). Latanoprost group presented the thickest glands (0,75 ± 0,10 mm upper and 0,94 ± 0,2 mm lower eyelid). The lowest Meiboscore in lower eyelid was Travoprost-Timolol (Polyquad) (59,7 ± 14,26%). Conclusions: Glaucoma Meibomian glands groups showed alterations compared to control. Polyquad showed less alterations in Meiboscore value than BAK groups, but not in all the parameters. Correlation with treatment but without cumulative preservative dose indicate another compounds effect. Upper eyelid glands seem to be affected earlier in these patients. Meibomian gland study should be considered as part of treatment decision and following in glaucoma patients.